



July 17th, 2015

ViperGen Enters into Drug Discovery Agreement with Bayer Pharma AG

Copenhagen, Denmark, July 17th, 2015 - - ViperGen ApS a biotechnology company focused on small molecule drug discovery using its proprietary 2nd generation DNA-encoded library platform, today announced the signing of a drug discovery agreement with Bayer Pharma AG (Bayer), the pharmaceutical division of Bayer HealthCare, one of the world's leading, innovative companies in the healthcare and medical products industry.

Under the terms of the agreement, ViperGen is applying its small molecule discovery engine, which leverages a high fidelity proprietary DNA-encoded library platform to identify novel hits/leads for selected targets from Bayer. Bayer obtains exclusive options to selected hits and hit series. The therapeutic area of the targets was not disclosed. No information about the financial arrangement was provided.

About ViperGen ApS

ViperGen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

ViperGen seeks to leverage its innovative and proprietary drug discovery platforms in partnerships with pharmaceutical and biotech companies.

ViperGen's two 2nd generation technology platforms - The YoctoReactor[®] for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment[®] for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor[®]/ Binder Trap Enrichment[®] drug discovery technology platforms please visit www.viperGen.com or contact:

ViperGen ApS

Dr. Nils Hansen, Chief Executive Officer

Phone: +45 2523 6680

nha@viperGen.com